@article{5fb9807c2bc1481a96a08adca183e756,
title = "Incidence of hypertension in obstructive sleep apnea using hypopneas defined by 3 percent oxygen desaturation or arousal but not by only 4 percent oxygen desaturation",
abstract = "Study Objectives: This analysis determined ~5-year incident hypertension rates using the 2017 American College of Cardiology/American Heart Association blood pressure (BP) guidelines in individuals with obstructive sleep apnea (OSA) with hypopneas defined by a = 3% oxygen desaturation or arousal but not by a hypopnea criterion of ≥ 4% oxygen desaturation (4% only). Methods: Data were analyzed from participants in the Sleep Heart Health Study exam 2 (n = 1219) who were normotensive (BP ≤ 120/80 mm Hg) at exam 1. The AHI at exam 1 was classified into 4 categories of OSA severity: < 5, 5 ≤ 15, 15 ≤ 30, and ≥ 30 events/h using both the 3% oxygen desaturation or arousal and the 4% only definitions. Three definitions of hypertension-elevated BP (> 120/80 mm Hg), stage 1 (> 130/80 mm Hg), and stage 2 (> 140/90 mm Hg)-were used to determine incidence rates at exam 2. Results: Five-year follow-up was available for 476 participants classified as having OSA by the 3% oxygen desaturation or arousal criterion but not by the 4% only standard at exam 1. Incident hypertension using American College of Cardiology/American Heart Association-defined BP categories in these discordantly classified individuals were 15%(elevated BP), 15%(stage 1), and 6% (stage 2). Hypertensive medications were used in 4% of participants who were normotensive. The overall incidence rate of at least an elevated BP was 40% (191/476) in those with OSA defined using the 3% oxygen desaturation or arousal criterion but not by the 4% only criterion. Conclusions: Use of the 4% only hypopnea definition resulted in the failure to identify a significant number of individuals with OSA who eventually developed hypertension and could have benefited from earlier diagnosis and treatment.",
keywords = "Berry RB, Budhiraja R, Hypopnea definition, Incident hypertension Citation, Javaheri S, OSA, Parthasarathy S, Quan SF. Incidence of hypertension in obstructive sleep apnea using hypopneas",
author = "Rohit Budhiraja and Sogol Javaheri and Sairam Parthasarathy and Berry, {Richard B.}",
note = "Funding Information: All authors have read and approved this manuscript. Work for this study was performed at Brigham and Women{\textquoteright}s Hospital and the University of Arizona College of Medicine. Dr. Budhiraja reports no conflicts of interest or grant funding. Dr. Javaheri serves as a consultant for Jazz Pharmaceuticals and Harmony Biosciences. Dr. Parthasarathy reports grants from the National Institutes of Health/National Heart, Lung and Blood Institute as the principal investigator (HL138377, HL126140; IPA-014264-00001; HL095799) or site PI (HL128954; UG3HL140144); other National Institutes of Health grants (AG059202, OD028307, HL151254); grants from the Patient Centered Outcomes Research Institute as the PI (IHS-1306-02505; EAIN-3394-UOA) or site investigator (PCS-1504-30430) and other grants (DI-2018C2-13161, PPRND-1507-31666) during the writing of the manuscript; grants from the U.S. Department of Defense as coinvestigator (W81XWH-14-1-0570); grants from the National Institutes of Health/ National Cancer Institute as coinvestigator (R21CA184920) and the National Institutes of Health/National Institute on Minority Health and Health Disparities as coinvestigator (MD011600); grants from the Johrei Institute; personal fees from the American Academy of Sleep Medicine; nonfinancial support from the National Center for Sleep Disorders Research of the National Institutes of Health (National Heart, Lung, and Blood Institute); personal fees from UpToDate Inc.; grants from Younes Sleep Technologies, Ltd.; personal fees from Vapotherm, Inc.; personal fees from Merck, Inc.; grants and personal fees from Philips-Respironics, Inc.; personal fees from Bayer, Inc.; personal fees from Nightbalance, Inc.; personal fees from Merck, Inc.; and grants from the American Academy of Sleep Medicine Foundation (169-SR-17). In addition, Dr. Parthasarathy has a patent issued (UA 14-018 U.S.S.N. 61/884,654; PTAS 502570970; home breathing device). Dr. Berry reports research funding from Philips Respironics, Res Med, and the University of Florida Foundation. Dr. Quan reports research funding from the National Institutes of Health, serves as a consultant to Jazz Pharmaceuticals and Whispersom, and is a committee chair and hypopnea task force member for the American Academy of Sleep Medicine. Funding Information: The Sleep Heart Health Study was supported by National Heart, Lung, and Blood Institute cooperative agreements U01HL53940 (University of Washington), U01HL53941 (Boston University), U01HL53938 (University of Arizona), U01HL53916 (University of California, Davis), U01HL53934 (University of Minnesota), U01HL53931 (New York University), U01HL53937 and U01HL64360 (Johns Hopkins University), U01HL63463 (Case Western Reserve University), and U01HL63429 (Missouri Breaks Research). A list of SHHS investigators, staff, and participating institutions is available on the SHHS website, http://jhuccs1.us/shhs/details/investigators.htm. Publisher Copyright: {\textcopyright} 2020 American Academy of Sleep Medicine. All rights reserved.",
year = "2020",
month = oct,
day = "15",
doi = "10.5664/jcsm.8684",
language = "English (US)",
volume = "6",
pages = "1753--1760",
journal = "Journal of Clinical Sleep Medicine",
issn = "1550-9389",
publisher = "American Academy of Sleep Medicine",
number = "10",
}